Genmab A/S (NASDAQ:GMAB - Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $20.32 and last traded at $20.34, with a volume of 53103 shares. The stock had previously closed at $20.65.
A number of equities research analysts have recently issued reports on the stock. Truist Financial reduced their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a "buy" rating for the company. Morgan Stanley reissued an "equal weight" rating and issued a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. BMO Capital Markets restated an "outperform" rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and an average price target of $45.20.
Read Our Latest Research Report on GMAB
The firm has a market cap of $13.43 billion, a price-to-earnings ratio of 20.05, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96. The business's fifty day moving average is $22.22 and its two-hundred day moving average is $25.14.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same period in the prior year, the business earned $0.47 earnings per share. Research analysts forecast that Genmab A/S will post 1.28 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the company. MML Investors Services LLC increased its stake in shares of Genmab A/S by 5.4% in the 3rd quarter. MML Investors Services LLC now owns 73,261 shares of the company's stock valued at $1,786,000 after acquiring an additional 3,785 shares in the last quarter. XTX Topco Ltd raised its position in Genmab A/S by 116.4% in the third quarter. XTX Topco Ltd now owns 25,429 shares of the company's stock worth $620,000 after acquiring an additional 13,678 shares during the period. Two Sigma Advisers LP lifted its holdings in Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after purchasing an additional 280,900 shares during the last quarter. Quantinno Capital Management LP grew its position in shares of Genmab A/S by 56.8% in the third quarter. Quantinno Capital Management LP now owns 24,207 shares of the company's stock valued at $590,000 after purchasing an additional 8,766 shares in the last quarter. Finally, HighTower Advisors LLC bought a new stake in Genmab A/S during the 3rd quarter worth approximately $273,000. Institutional investors and hedge funds own 7.07% of the company's stock.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.